Looking ahead, Xeris Pharmaceuticals projects total revenue for 2025 to be between $255 million and $275 million, indicating a potential growth of approximately 30%. Supporting this optimistic outlook, InvestingPro reports that two analysts have recently revised their earnings estimates upward for the upcoming period. The company maintains a "GOOD" Financial Health Score of 2.94, suggesting solid fundamentals despite current non-profitability. The company anticipates continued growth in its Recorlev and Gevo products, with steady performance expected from KEVEYIS. Preparations for the Phase 3 development of XP8121, a hypothyroidism treatment, are also underway, with potential clinical trials starting in 2026.